AVROBIO, Inc. (AVRO) |
|
1 0.064 (6.78%)
|
03-31 16:00 |
|
Open: |
0.95 |
Pre. Close: |
0.9365 |
|
High:
|
1 |
Low:
|
0.94 |
|
Volume:
|
170,550 |
Market Cap:
|
44(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:16:56 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.46 One year: 1.76 |
| Support: |
Support1: 0.84 Support2: 0.69 |
| Resistance: |
Resistance1: 1.25 Resistance2: 1.5 |
| Pivot: |
1.11  |
| Moving Average: |
MA(5): 1.01 MA(20): 1.17
MA(100): 1.01 MA(250): 0.94 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 23.3 %D(3): 26.8 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 1.92 Low: 0.56 |
| Average Vol(K): |
3-Month: 1,340 (K) 10-Days: 517 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AVRO ] has closed above bottom band by 27.4%. Bollinger Bands are 30.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.99 - 1 |
1 - 1 |
|
Low:
|
0.89 - 0.89 |
0.89 - 0.9 |
|
Close:
|
0.93 - 0.94 |
0.94 - 0.95 |
|
Company Description |
|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Thu, 30 Mar 2023
Dyadic Internationals Financial and Operational Results for 2021 ... - Best Stocks
Thu, 23 Mar 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... - Investing.com
Thu, 23 Mar 2023
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial ... - Business Wire
Tue, 21 Mar 2023
Is Avrobio Inc (AVRO) a Good Buy in the Healthcare Sector? - InvestorsObserver
Fri, 03 Mar 2023
Is it Time to Dump Avrobio Inc (AVRO) Stock After it Is Up 3.62% in a Week? - InvestorsObserver
Fri, 03 Mar 2023
AVROBIO to Participate in Cowen's 43rd Annual Health Care ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
44 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
2.6 (%) |
|
% Held by Institutions
|
53 (%) |
|
Shares Short
|
424 (K) |
|
Shares Short P.Month
|
125 (K) |
Stock Financials |
|
EPS
|
-2.47 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.24 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-39.1 |
|
Return on Equity (ttm)
|
-74.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.44 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-99 (M) |
|
Levered Free Cash Flow
|
-61 (M) |
Stock Valuations |
|
PE Ratio
|
-0.41 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.44 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
